Progress in Assays of HMGB1 Levels in Human Plasma-The
Potential Prognostic Value in COVID-19

J 2022

Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19

ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ a Petr SKLÁDAL

Základní údaje

Originální název

Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19

Autoři

ŠTROS, Michal (garant), Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ (203 Česká republika, domácí) a Petr SKLÁDAL (203 Česká republika, domácí)

Vydání

Biomolecules, Basel, MDPI, 2022, 2218-273X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10601 Cell biology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.500

Kód RIV

RIV/00216224:14310/22:00126405

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.3390/biom12040544

UT WoS

000787419100001

Klíčová slova anglicky

HMGB1; plasma/serum; ELISA; EMSA; immunosensor; COVID-19

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 8. 2022 14:29, Mgr. Marie Šípková, DiS.

Anotace

V originále

Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.

Návaznosti

NU20-08-00106, projekt VaV

Název: Elektrochemický imunodetektor pro detekci HMGB1 v séru pacientů s různými formami leukémie: metoda pro rychlé zhodnocení úspěšnosti léčby

Investor: Ministerstvo zdravotnictví ČR, Elektrochemický imunodetektor pro detekci HMGB1 v séru pacientů s různými formami leukémie: metoda pro rychlé zhodnocení úspěšnosti léčby, Podprogram 1 - standardní

Citovat

ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ a Petr SKLÁDAL. Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19. Biomolecules. Basel: MDPI, 2022, roč. 12, č. 4, s. 1-11. ISSN 2218-273X. Dostupné z: https://dx.doi.org/10.3390/biom12040544.

@article{2210924,
   author = {Štros, Michal and Volfová Polanská, Eva and Hlaváčová, Tereza and Skládal, Petr},
   article_location = {Basel},
   article_number = {4},
   doi = {http://dx.doi.org/10.3390/biom12040544},
   keywords = {HMGB1; plasma/serum; ELISA; EMSA; immunosensor; COVID-19},
   language = {eng},
   issn = {2218-273X},
   journal = {Biomolecules},
   title = {Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19},
   url = {https://www.mdpi.com/2218-273X/12/4/544},
   volume = {12},
   year = {2022}
}

TY  - JOUR
ID  - 2210924
AU  - Štros, Michal - Volfová Polanská, Eva - Hlaváčová, Tereza - Skládal, Petr
PY  - 2022
TI  - Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19
JF  - Biomolecules
VL  - 12
IS  - 4
SP  - 1-11
EP  - 1-11
PB  - MDPI
SN  - 2218273X
KW  - HMGB1
KW  - plasma/serum
KW  - ELISA
KW  - EMSA
KW  - immunosensor
KW  - COVID-19
UR  - https://www.mdpi.com/2218-273X/12/4/544
N2  - Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.
ER  -

ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ a Petr SKLÁDAL. Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19. \textit{Biomolecules}. Basel: MDPI, 2022, roč.~12, č.~4, s.~1-11. ISSN~2218-273X. Dostupné z: https://dx.doi.org/10.3390/biom12040544.

Podrobný výpis o publikaci